InsiderClue
← All stocks

Aardvark Therapeutics, Inc.

AARD Net buying
CIK 0001774857 #4182 in the set updated 17 Sep 2026
Bought (120 mo)
$23.87M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$394.96K
$394.96K on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 2 sales
Net
+$23.48M
+$23.87M against sales at will

By person

7 insiders · 18 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Decheng Capital Global Life Sciences Fund IV, L.P. entity
10% owner
$20.00M (2)
—
+$20.00M
958,412
4.38%
$4.96M
—
Cormorant Asset Management, LP entity
Former 10% Owner
$3.00M (1)
—
+$3.00M
987,689
4.51%
$5.12M
—
Lee Tien-Li
Chief Executive Officer
$623.34K (7)
—
+$623.34K
1,551,613
7.09%
$8.04M
+7.9%
Sun Nelson
See Remarks
$251.64K (3)
$394.96K (2) scheduled
−$143.32K
35,475
0.1621%
$183.77K
−58.9%
Vickers Venture Fund VI Pte Ltd entity
10% owner
—
—
—
2,050,902
9.37%
$10.62M
—
Chi Jeffrey
Director
—
—
—
133,364
0.6094%
$690.87K
—
Jones Bryan
Chief Operating Officer
—
—
—
1,250
0.0057%
$6.48K
—

Individual transactions

13
Insider
Date
Role
Action
Shares
Price
Amount
Lee Tien-Li
11 Dec 2025
Chief Executive Officer
Buy
7,000
$14.49
$101.40K
Sun Nelson
11 Dec 2025
Chief Financial Officer
Buy
3,000
$14.40
$43.20K
Lee Tien-Li
15 Sep 2025
Chief Executive Officer
Buy
3,500
$9.94
$34.80K
Lee Tien-Li
15 Sep 2025
Chief Executive Officer
Buy
6,500
$9.51
$61.82K
Lee Tien-Li
12 Sep 2025
Chief Executive Officer
Buy
5,000
$8.50
$42.52K
Lee Tien-Li
11 Sep 2025
Chief Executive Officer
Buy
6,000
$7.82
$46.93K
Lee Tien-Li
10 Sep 2025
Chief Executive Officer
Buy
9,000
$7.91
$71.21K
Sun Nelson
9 Sep 2025
Chief Financial Officer
Buy
6,000
$8.07
$48.44K
Cormorant Asset Management, LP
14 Feb 2025
Former 10% Owner
Buy indirect
187,500
$16.00
$3.00M
Sun Nelson
14 Feb 2025
Chief Financial Officer
Buy
10,000
$16.00
$160.00K
Lee Tien-Li
14 Feb 2025
Chief Executive Officer
Buy
16,542
$16.00
$264.67K
Decheng Capital Global Life Sciences Fund IV, L.P.
14 Feb 2025
10% owner
Buy indirect
625,000
$16.00
$10.00M
Decheng Capital Global Life Sciences Fund IV, L.P.
14 Feb 2025
10% owner
Buy indirect
625,000
$16.00
$10.00M
Show all 18 transactions →

What was left out

Form 4 filings counted 30
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 5,719,746
History held since 19 Feb 2025